سامانه مدیریت نشریات علمی دانشگاه علوم پزشکی مشهد

Farokhimanesh, Samila, Forouzandeh Moghadam, Mehdi, Ebrahimi, Marzieh. (1398). Metastasis inhibition by BRMS1 and miR-31 replacement therapy in claudin-low cell lines. , 23(2), 264-270. doi: 10.22038/ijbms.2019.35674.8500
Samila Farokhimanesh; Mehdi Forouzandeh Moghadam; Marzieh Ebrahimi. "Metastasis inhibition by BRMS1 and miR-31 replacement therapy in claudin-low cell lines". , 23, 2, 1398, 264-270. doi: 10.22038/ijbms.2019.35674.8500
Farokhimanesh, Samila, Forouzandeh Moghadam, Mehdi, Ebrahimi, Marzieh. (1398). 'Metastasis inhibition by BRMS1 and miR-31 replacement therapy in claudin-low cell lines', , 23(2), pp. 264-270. doi: 10.22038/ijbms.2019.35674.8500
Farokhimanesh, Samila, Forouzandeh Moghadam, Mehdi, Ebrahimi, Marzieh. Metastasis inhibition by BRMS1 and miR-31 replacement therapy in claudin-low cell lines. , 1398; 23(2): 264-270. doi: 10.22038/ijbms.2019.35674.8500

Metastasis inhibition by BRMS1 and miR-31 replacement therapy in claudin-low cell lines

Iranian Journal of Basic Medical Sciences
مقاله 16، دوره 23، شماره 2، اردیبهشت 2020، صفحه 264-270    اصل مقاله (743.42 K)
نوع مقاله: Original Article
شناسه دیجیتال (DOI): 10.22038/ijbms.2019.35674.8500
نویسندگان
Samila Farokhimanesh1، 2؛ Mehdi Forouzandeh Moghadam* 1؛ Marzieh Ebrahimi3
1Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
2Department of Biotechnology, Science and Research Branch, Islamic Azad Unversity, Tehran, Iran
3Department of Stem Cells and Developmental Biology at Cell Science Research Center, Royan Institute for StemCell Biology and Technology, ACECR, Tehran, Iran
چکیده
Objective(s): The growing trend of research demonstrates that dynamic expression of two metastasis repressor classes (metastasis suppressor genes and anti-metastatic miRNA) has a close relationship with tumor invasion and metastasis. Using different strategies, it was revealed that cellular levels of miR-31 and Breast cancer Metastasis Suppressor1 (BRMS1) protein, which are among the most significant modulators of metastasis, have a correlation with the cell’s capability for invading and metastasizing; cells containing higher levels of miR-31 or BRMS1 were less metastatic. This project was carried out to determine whether the combinations of miR-31 and BRMS1 genes are able to enhance the capability of repressing the claudin-low breast cancer cell (MDA-MB-231) invasion. Materials and Methods: This study used a restoration-based approach by miR-31 mimic and optimized BRMS1 gene sequences, which were cloned into a chimeric construct and transfected to the MDA-M231cells.
Results: Our data revealed that the simultaneous expression of anti-metastasis miR and metastasis suppressor might inhibit migration and invasion in MDA-MB-231 cells efficiently.
Conclusion: This combinatorial use of anti-metastatic miR and gene suggests a new therapeutic intervention for metastasis inhibition in MDA-MB-231.
کلیدواژه‌ها
Breast cancer؛ BRMS1؛ miR 31؛ Neoplasm metastasis؛ Replacement therapy
مراجع
1. Kodura MA, Souchelnytskyi S. Breast carcinoma metastasis suppressor gene 1 (BRMS1): update on its role as the suppressor of cancer metastases. Cancer Metastasis Rev 2015; 34:611-618.
2. Welch D, Manton C, Hurst D. Breast Cancer Metastasis Suppressor 1 (BRMS1): Robust biological and pathological data, but still enigmatic mechanism of action. Adv Cancer Res 2016; 132:111-137.
3. Hashemi ZS, Moghadam MF, Khalili S, Ghavami M, Salimi F, Sadroddiny E. Additive effect of metastamiR-193b and breast cancer metastasis suppressor 1 as an anti-metastatic strategy. Breast Cancer 2019; 26:215-228.
4. Edmonds MD, Hurst DR, Vaidya KS, Stafford LJ, Chen D, Welch DR. Breast cancer metastasis suppressor 1 coordinately regulates metastasis‐associated microRNA expression. Int J Cancer 2009; 125:1778-1785.
5. Edmonds MD, Hurst DR, Welch DR. Linking metastasis suppression with metastamiR regulation. Cell cycle 2009; 8:2673-2675.
6. Hashemi ZS, Khalili S, Forouzandeh Moghadam M, Sadroddiny E. Lung cancer and miRNAs: a possible remedy for anti-metastatic, therapeutic and diagnostic applications. Expert Rev Respir Med 2017; 11:147-157.
7. Schmittgen TD. miR-31: a master regulator of metastasis? Future Oncol 2010; 6:17-20.
8. Körner C, Keklikoglou I, Bender C, Wörner A, Münstermann E, Wiemann S. MicroRNA-31 sensitizes human breast cells to apoptosis by direct targeting of protein kinase C ϵ (PKCϵ). J Biol Chem 2013; 288:8750-8761.
9. Farokhimanesh S, Forouzandeh Moghadam M, Ebrahimi M. Inhibition of breast cancer metastasis by using miR-31-mimic in cancer stem cell rich MDA-MB231 cell line.Tehran Univ Med J 2015; 73:1-10.
10. Sossey‐Alaoui K, Downs‐Kelly E, Das M, Izem L, Tubbs R, Plow EF. WAVE3, an actin remodeling protein, is regulated by the metastasis suppressor microRNA, miR‐31, during the invasion‐metastasis cascade. Int J Cancer 2011; 129:1331-1343.
11. Augoff K, Das M, Bialkowska K, McCue B, Plow EF, Sossey-Alaoui K. MiR-31 is a broad regulator of β1-integrin expression and function in cancer cells. Mol Cancer Res 2011; 9:1500-1508.
12. Luo LJ, Yang F, Ding JJ, Yan DL, Wang DD, Yang SJ, et al. MiR-31 inhibits migration and invasion by targeting SATB2 in triple negative breast cancer. Gene 2016; 594:47-58.
13. Hashemi ZS, Moghadam MF, Farokhimanesh S, Rajabibazl M, Sadroddiny E. Inhibition of breast cancer metastasis by co-transfection of miR-31/193b-mimics. Iran J Basic Med Sci 2018; 21:427-433.
14. Hashemi ZS, Moghadam MF, Sadroddiny E. Varying miR-193b-3p expression patterns in breast cancer cell Lines indicates its potential for cancer management strategies. Int J Cancer Manag 2018; 11:1-9.
15. Henry JC, Azevedo-Pouly ACP, Schmittgen TD. MicroRNA replacement therapy for cancer. Pharm Res 2011; 28:3030-3042.
16. Kasinski AL, Slack FJ. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011; 11:849-864.
17. Kay MA. State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet 2011; 12:316-328.
18. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007; 39:673-677.
19. van Rooij E, Purcell AL, Levin AA. Developing microRNA therapeutics. Circ Res 2012; 110:496-507.
20. Dittmer J. Mechanisms governing metastatic dormancy in breast cancer. Semin Cancer Biol 2017; 44:72-82.
21. Idowu MO, Kmieciak M, Dumur C, Burton RS, Grimes MM, Powers CN, et al. CD44+/CD24−/low cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol 2012; 43:364-373.
22. Mylona E, Giannopoulou I, Fasomytakis E, Nomikos A, Magkou C, Bakarakos P, et al. The clinicopathologic and prognostic significance of CD44+/CD24−/low and CD44−/CD24+ tumor cells in invasive breast carcinomas. Hum Pathol 2008; 39:1096-1102.
23. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, et al. CD44+/CD24-breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 2006; 8: R59.
24. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005; 65:5506-5511.
25. Raza U, Zhang JD, Şahin Ö. MicroRNAs: master regulators of drug resistance, stemness, and metastasis. J Mol Med 2014; 92:321-336.
26. Valastyan S, Weinberg RA. MiR-31: a crucial overseer of tumor metastasis and other emerging roles. Cell Cycle 2010; 9:2124-2129.
27. Zhang Y, Ye L, Tan Y, Sun P, Ji K, Jiang WG. Expression of breast cancer metastasis suppressor-1, BRMS-1, in human breast cancer and the biological impact of BRMS-1 on the migration of breast cancer cells. Anticancer Res 2014; 34:1417-1426.

آمار
تعداد مشاهده مقاله: 879
تعداد دریافت فایل اصل مقاله: 452